Sun Pharma Reports a Profit for Q1

By Olga Robert
Subscribe to GoodReturns
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    Sun Pharmaceutical Industries Ltd. in a stock exchange filing reported a net profit of Rs 983 crore for the April-June quarter against a loss of Rs 425 crore in the same period last year. For the year-ago period, the company had reported an exceptional loss of Rs 950 crore in the base quarter due to litigation provisions.

    Sun Pharma Reports a Profit for Q1

    India's largest drugmaker is awaiting for approvals from the FDA for two specialty products from its Halol facility which was cleared by the U.S. drug regulator earlier this year.

    In a statement accompanying the filing the company's managing director said, "We are gradually crossing key milestones in our specialty initiatives with the recent commercialisation of Yonsa (cancer drug) in the U.S. and targeted launch of Ilumya (skin condition drug) and Cequa (eye drug) in the coming quarters."

    The company's revenue for the quarter grew by 16 percent on a year-on-year basis to Rs 7,224 crore, while other income was up by 31 percent to Rs 199 crore from last year. Its finance costs increased by 20 percent to Rs 131 crore.

    The EBITDA for the quarter under review rose by 47 percent to Rs 1,607 crore, while margin expanded 460 basis points to 22.2 percent.

    Sun Pharma's sales in India were up by 22 percent to Rs 2,152 crore from last year, while U.S. finished dosage sales were up 8 percent to $380 million.

    Shares of Sun Pharma were trading higher after the result announcement.

    Read more about: sun pharma
    Story first published: Tuesday, August 14, 2018, 17:07 [IST]
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    Get Latest News alerts from Goodreturns

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more